|
1) Montuschi P, Sala A, Dahlen SE, et al. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today. 2007; 12: 404-12
|
|
|
|
2) Kim DC, Hsu FI, Barrett NA, et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol. 2006; 176: 4440-8
|
|
|
|
|
|
3) Stelmach I, Bobrowska-Korzeniowska M, Majak P, et al. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulm Pharmacol Ther. 2005; 18: 374-80
|
|
|
|
|
|
4) Zhu J, Qiu YS, Figueroa DJ, et al. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol. 2005; 33: 531-40
|
|
|
|
|
|
5) Machida I, Matsuse H, Kondo Y, et al. Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J Immunol. 2004; 172: 1833-8
|
|
|
|
|
|
6) Faith A, Fernandez MH, Caulfield J, et al. Role of cysteinyl leukotrienes in human allergen-specific Th2 responses induced by granulocyte macrophage-colony stimulating factor. Allergy. 2008; 63: 168-75
|
|
|
|
|
|
7) Okunishi K, Dohi M, Nakagome K, et al. A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. J Immunol. 2004; 173: 6393-402
|
|
|
|
|
|
8) Kuitert LM, Newton R, Barnes NC, et al. Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis. Thorax. 1996; 51: 1223-8
|
|
|
|
|
|
9) Sousa A, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax. 1997; 52: 940-5
|
|
|
|
|
|
10) Profita M, Sala A, Bonanno A, et al. Increased prostaglandin E2 concentrations and cyclo-oxygenase-2 expression in asthmatic subjects with sputum eosinophilia. J Allergy Clin Immunol. 2003; 112: 709-16
|
|
|
|
|
|
11) Chung KF. Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic agents for the treatment of asthma. Sci STKE. 2005; 303: pe47
|
|
|
|
|
|
12) Tilley SL, Hartney JM, Erikson CJ, et al. Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol. 2003; 284: L599-606
|
|
|
|
|
|
13) Mathe AA, Hedqvist P. Effect of prostaglandins F2 alpha and E2 on airway conductance in healthy subjects and asthmatic patients. Am Rev Respir Dis. 1975; 111: 313-20
|
|
|
|
|
|
14) Penn RB, Pascual RM, Kim YM, et al. Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. J Biol Chem. 2001; 276: 32648-56
|
|
|
|
|
|
15) Deshpande DA, Theriot BS, Penn RB, et al. Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscle. Faseb J. 2008; 22: 2134-41
|
|
|
|
|
|
16) McGraw DW, Mihlbachler KA, Schwarb MR, et al. Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest. 2006; 116: 1400-9
|
|
|
|
|